File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Molecular detection of minimal residual disease for patients with leukemia and lymphoma

TitleMolecular detection of minimal residual disease for patients with leukemia and lymphoma
Authors
KeywordsNeoplasm, residual
Leukaemia
Lymphoma
Polymerase chain reaction
Issue Date1997
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org.hk
Citation
Hong Kong Medical Journal, 1997, v. 3 n. 2, p. 195-200 How to Cite?
AbstractAlthough a complete clinical remission can often be achieved with chemotherapy for patients with leukaemia and lymphoma, relapses still occur. Residual tumour cells probably have survived therapy and account for subsequent disease relapse. The sensitivity of conventioned ways of detecting residual tumour cells, such as morphological studies, immunophenotyping, and cytogenetics, is only about 1% to 5% and may be inadequate. Polymerase chain reaction technology had provided a simple and highly sensitive means for the detection of minimal residual disease. The technology has been successfully applied to study biopsy samples obtained from patients with leukaemia and lymphpma. Its clinical usefulness, however, requires further evaluation by prospective clinical studies.
Persistent Identifierhttp://hdl.handle.net/10722/45045
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorLiang, RHSen_HK
dc.contributor.authorChan, DWen_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorChan, VNYen_HK
dc.date.accessioned2007-10-30T06:16:18Z-
dc.date.available2007-10-30T06:16:18Z-
dc.date.issued1997en_HK
dc.identifier.citationHong Kong Medical Journal, 1997, v. 3 n. 2, p. 195-200en_HK
dc.identifier.issn1024-2708en_HK
dc.identifier.urihttp://hdl.handle.net/10722/45045-
dc.description.abstractAlthough a complete clinical remission can often be achieved with chemotherapy for patients with leukaemia and lymphoma, relapses still occur. Residual tumour cells probably have survived therapy and account for subsequent disease relapse. The sensitivity of conventioned ways of detecting residual tumour cells, such as morphological studies, immunophenotyping, and cytogenetics, is only about 1% to 5% and may be inadequate. Polymerase chain reaction technology had provided a simple and highly sensitive means for the detection of minimal residual disease. The technology has been successfully applied to study biopsy samples obtained from patients with leukaemia and lymphpma. Its clinical usefulness, however, requires further evaluation by prospective clinical studies.en_HK
dc.format.extent394517 bytes-
dc.format.extent517067 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypeapplication/pdf-
dc.languageengen_HK
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org.hken_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectNeoplasm, residualen_HK
dc.subjectLeukaemiaen_HK
dc.subjectLymphomaen_HK
dc.subjectPolymerase chain reactionen_HK
dc.titleMolecular detection of minimal residual disease for patients with leukemia and lymphomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1024-2708&volume=3&issue=2&spage=195&epage=200&date=1997&atitle=Molecular+detection+of+minimal+residual+disease+for+patients+with+leukemia+and+lymphomaen_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid11850571en_HK
dc.identifier.hkuros25479-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats